Lunai Bioworks Inc (LNAI) Stock Price, Quote & News

Company Profile

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform...

Phone: 305 918 1980

Website: renovarogroup.com

Address:

2080 Century Park East, Suite 906, Los Angeles, United States

Whales22 Oct. 24 at 8:41 PM

How much volume do you think it takes to gap CMCT up? CMCT has not even 700K shares float and recent news. Hoping for a 100% run on CMCT $POAI $LNAI $ORKT $LESL Watchlist/

0 · Reply

My_Lai_1968 Oct. 24 at 6:13 AM

$LNAI Could anyone tell me if this company still makes fallopian tubes for women who are born without a pelvis?

1 · Reply

Nottrue Oct. 23 at 7:24 PM

$LNAI @luca3211@marketforecsting I am tired of Marketforecasting.Biosymetrics is not a fraudulent company and they have labs ,I have seen it and real peple and real orders .Ip ersonally have seen it .Marketforecaasting must be an old soul who thinks if terms of office spaces. Phew I am not responding to his nonsense any more.He knows nothing about science and wants everyone to short.I do not like people who act like that.I am not sying Lunia is perfect ,I said over and over the topco CEO is an arrogant, non commuunocator tha tthinks the world of himself, but the world does not think the same.

0 · Reply

MarketForecasting Oct. 23 at 5:19 PM

$LNAI I believe either this month or next month they will begin the bankruptcy proceedings .

1 · Reply

Nottrue Oct. 23 at 1:04 PM

$LNAI @luca3211 of course they are not filing for Chapter 11.It is apity that people say these thingds to short and make money and in meantime try to destroy a companu with really good potnetial to stop progression of neurological diseases and make a real social impact. Yes they made a lot of mistakes at Lunai and in particualr their top management and people around them but tha tis not reason to write garbage and disqualify biosymetrics and theor really good sicience and leadership team.

1 · Reply

11thestate Oct. 23 at 12:02 PM

$LNAI has reached a $2.5M settlement with $ENOB investors over claims that it concealed its co-founder’s lack of proper credentials and criminal history. The filing deadline is December 7, 2025. If you bought $ENOB between January 17, 2018, and June 27, 2022, you can file for payment here: https://11th.com/cases/enochian-biosciences-investor-settlement?utm_source=stocktwits&utm_medium=referral&utm_campaign=ddl&utm_content=10232025_1

0 · Reply

Whales22 Oct. 23 at 7:52 AM

How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $YAAS $RAYA $POAI $LNAI Watchlist \

0 · Reply

MarketForecasting Oct. 23 at 7:40 AM

$LNAI Preparing to file for Chapter 11

0 · Reply

Shine1313 Oct. 23 at 7:37 AM

$LNAI let's pop

0 · Reply

Luca3211 Oct. 22 at 9:05 PM

$LNAI what is going on?

0 · Reply

Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics

Oct 16, 2025, 9:15 AM EDT - 9 days ago

Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

Oct 6, 2025, 9:15 AM EDT - 19 days ago

Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline

Sep 30, 2025, 9:15 AM EDT - 25 days ago

Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense

Sep 25, 2025, 8:30 AM EDT - 4 weeks ago

Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships

Sep 24, 2025, 4:50 PM EDT - 4 weeks ago

Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split

Sep 11, 2025, 7:00 AM EDT - 6 weeks ago

Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics

Sep 9, 2025, 9:12 AM EDT - 6 weeks ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

CERO SMMT

Sep 9, 2025, 8:47 AM EDT - 6 weeks ago

Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery

Sep 8, 2025, 8:50 AM EDT - 6 weeks ago

Lunai Bioworks Strengthens European Strategy Through Restructuring

Sep 4, 2025, 10:05 AM EDT - 7 weeks ago

Lunai Bioworks Inc. Retains American Defense International

Aug 27, 2025, 9:45 AM EDT - 2 months ago

Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics

Aug 8, 2025, 10:45 AM EDT - 2 months ago

Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks

Jul 28, 2025, 10:38 AM EDT - 3 months ago

Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector

Jul 17, 2025, 9:15 AM EDT - 3 months ago

Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

Jul 9, 2025, 8:00 AM EDT - 3 months ago

Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

Jun 30, 2025, 9:21 AM EDT - 4 months ago

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

Jun 3, 2025, 9:15 AM EDT - 5 months ago

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

May 22, 2025, 3:12 PM EDT - 5 months ago

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 22, 2025, 11:05 AM EDT - 5 months ago

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 14, 2025, 9:15 AM EDT - 5 months ago

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

May 13, 2025, 9:15 AM EDT - 5 months ago

Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics

Apr 22, 2025, 9:20 AM EDT - 6 months ago

Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

Apr 9, 2025, 9:25 AM EDT - 7 months ago

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Apr 4, 2025, 9:40 AM EDT - 7 months ago

Renovaro Provides Update to Definitive Agreement with Predictive Oncology

Mar 3, 2025, 9:15 AM EST - 8 months ago

Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology

Feb 26, 2025, 1:25 PM EST - 8 months ago

Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

Feb 26, 2025, 9:15 AM EST - 8 months ago

Renovaro Announces $15 million in Equity Committed

Jan 7, 2025, 6:51 PM EST - 10 months ago

PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI

POAI

Jan 7, 2025, 9:15 AM EST - 10 months ago

Renovaro Appoints Nathen Fuentes as Chief Financial Officer

Jan 7, 2025, 9:15 AM EST - 10 months ago

Renovaro Issues Shareholder Letter and Provides Corporate Update

Jan 6, 2025, 9:15 AM EST - 10 months ago

Renovaro to Acquire Predictive Oncology in All-Stock Transaction

Dec 30, 2024, 9:00 AM EST - 10 months ago

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Dec 23, 2024, 9:00 AM EST - 10 months ago

RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program

Dec 20, 2024, 3:40 PM EST - 11 months ago

Renovaro Regains Compliance with NASDAQ Listing Requirement

Dec 20, 2024, 9:00 AM EST - 11 months ago

Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

Oct 17, 2024, 9:15 AM EDT - 1 year ago

RenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing

Oct 16, 2024, 9:28 AM EDT - 1 year ago

Renovaro Announces Strategic Restructuring and Leadership Transition

Sep 13, 2024, 9:00 AM EDT - 1 year ago

RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress

Sep 11, 2024, 9:15 AM EDT - 1 year ago

RenovaroCube Announces Strategic Offering of Up to 20% Ownership

Jun 14, 2024, 9:06 AM EDT - 1 year ago

Renovaro, Inc. Announces $10 million in Equity Committed

May 24, 2024, 9:20 AM EDT - 1 year ago

Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy

May 21, 2024, 8:39 AM EDT - 1 year ago

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB)

BAX RAPT SAGE TMCI

Apr 30, 2024, 11:00 AM EDT - 1 year ago

Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics

Apr 24, 2024, 9:00 AM EDT - 1 year ago

RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership

Apr 18, 2024, 8:45 AM EDT - 1 year ago

Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient C

Feb 15, 2024, 9:25 AM EST - 1 year ago

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

Feb 14, 2024, 10:01 AM EST - 1 year ago

Statement of Renovaro Inc

Feb 13, 2024, 9:31 AM EST - 1 year ago

AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine

Whales22 Oct. 24 at 8:41 PM

How much volume do you think it takes to gap CMCT up? CMCT has not even 700K shares float and recent news. Hoping for a 100% run on CMCT $POAI $LNAI $ORKT $LESL Watchlist/

0 · Reply

My_Lai_1968 Oct. 24 at 6:13 AM

$LNAI Could anyone tell me if this company still makes fallopian tubes for women who are born without a pelvis?

1 · Reply

Nottrue Oct. 23 at 7:24 PM

0 · Reply

MarketForecasting Oct. 23 at 5:19 PM

$LNAI I believe either this month or next month they will begin the bankruptcy proceedings .

1 · Reply

Nottrue Oct. 23 at 1:04 PM

1 · Reply

11thestate Oct. 23 at 12:02 PM

0 · Reply

Whales22 Oct. 23 at 7:52 AM

How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $YAAS $RAYA $POAI $LNAI Watchlist \

0 · Reply

MarketForecasting Oct. 23 at 7:40 AM

$LNAI Preparing to file for Chapter 11

0 · Reply

Shine1313 Oct. 23 at 7:37 AM

$LNAI let's pop

0 · Reply

Luca3211 Oct. 22 at 9:05 PM

$LNAI what is going on?

0 · Reply

Shine1313 Oct. 22 at 8:42 PM

$LNAI touched bottom

0 · Reply

Nottrue Oct. 22 at 8:26 PM

@Stengaard1 $LNAI you are very silent Stengaard ,a good company bad managment is being relentlessy shorted and attacked.Time they come with news and a short squeeze ,unless they are going for this low price game.

0 · Reply

MarketForecasting Oct. 22 at 7:05 PM

$LNAI total scam like I said ..

0 · Reply

MarketForecasting Oct. 22 at 6:43 PM

$LNAI 🤣🤣👌 this short still has meat on it

0 · Reply

Nottrue Oct. 21 at 8:37 PM

$LNAI the ADI announcement pretty much fits into the description of what Biosymetrics acheived,they just have not announced it..no idea why they have not made this release yet found this on the ADI own website

0 · Reply

Nottrue Oct. 21 at 8:36 PM

$LNAI BUSINESS DEVELOPMENT + GOVERNMENT RELATIONS ISSUE: One of ADI’s clients wanted to expand its business in the Department of Defense by building a program to protect against biological attacks using unknown pathogens. STRATEGY: Working with its client, ADI launched a comprehensive business development and government relations plan to create and grow the program within the United States Army. ADI worked with the client and the Army to establish support for the program. RESULT: ADI was able to successfully create an ongoing program, including multi-year funding to initiate the effort. The client’s program is now fully funded in the annual Department of Defense budget request for over $100 million.

0 · Reply

Nottrue Oct. 21 at 8:00 PM

$LNAI looks like a short squeeze is coming...

0 · Reply

Nottrue Oct. 21 at 6:23 PM

$LNAI they will make it so no reason to short no monie in it,just new management tha tis all hta tis needed

0 · Reply

MarketForecasting Oct. 21 at 6:05 PM

$LNAI there is an old saying , “know what you own”, well know that this is a fake company that will declare bankruptcy and get delisted .

0 · Reply

Nottrue Oct. 19 at 5:28 AM

$LNAI @Stengaard1 Lunai bioworks may have changed their name but they are still misleading the pack.Why do none of you read the 8Q/10K/AGM and question why parties and their companies get co many shares just recently.How could the board approve a 65 percent uplift?Stengaard,sorry but Gedi Cube should never have been closed they weer near to a JV with UMc Amsterdam ,had a super ogvernment grant,their costs were lower than biotech or the worthless CEO of the group and they had developed other potential that is now orth hundreds of millions but was disregarded.Stengaard is time you and your friends do not accept what you are whispered.This all is a big shame. On the other hand Biosymetrics is a winner also and all their geat announcemnts do not move the share price. Gabe Musso should become the new CEO or executive Chairman. that will breed confidence.

0 · Reply

Stengaard1 Oct. 18 at 6:46 PM

$LNAI It would be nice if Lunai speeded up the partnership negotiations on the ground breaking cancer therapy before it is overtaken by AI https://x.com/nexta_tv/status/1979286294724514211

1 · Reply

Nottrue Oct. 17 at 8:51 PM

$LNAI @Stengaard1 wake up with your predictions which are told to you so you spread fake news.The AGM hoefully people will ask critical questions.Cube was doing fine and had a good future.Their costs were 1/3 of Biotech and 1/5 of Topco .You have no idea what you are talking about but just repeat what you are whispered .Het your own opinions be a little critical

0 · Reply

Market Cap	24.11M
Revenue (ttm)	0.00
Net Income (ttm)	-178.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	182,600
Avg Vol	271,126
Day's Range	N/A - N/A
Shares Out	23.18M
Stochastic %K	36%
Beta	0.39
Analysts	Strong Buy
Price Target	N/A